Chinese Innovative Medical Devices Go Global as Lujian Technology Enters the Leading Ranks of CDMO

Recently, Lujian Technology has continued to expand its global footprint. By introducing internationally advanced technologies and transforming them into R&D, manufacturing, and global export capabilities, the company has successfully entered the leading ranks of global medical device CDMOs.

Joining the Core Global CDMO Camp

As the exclusive global manufacturer of an innovative Israeli medical device, Lujian Technology has made another major breakthrough following the product’s FDA approval. Its subsidiary, Sichuan Innovation Technology Co., Ltd., has successfully completed FDA listing in the United States, officially becoming the certified contract manufacturer and contract sterilizer for the product.

This is more than a certification; it is an authoritative endorsement of the production system, quality management, and international compliance capabilities of Lujian Technology and Sichuan Innovation Technology Co., Ltd. It also marks the establishment of Lujian’s full-process service ecosystem, with CDMO as its strategic core engine, covering medical device technology introduction, R&D transformation, registration application, industrialization, and global market promotion.

Lujian Technology is now capable of providing global clients with high-standard, integrated, and compliant R&D transformation and high-end manufacturing services, officially joining the leading ranks of global medical device CDMOs.

From Qualification Approval to Multi-Market Global Deployment

If qualification is the entry ticket, the market is the true test. Recently, the first batch of TroClose 1200 products departed from the Chengdu Economic and Technological Development Zone and was shipped overseas to the United States, Israel, Singapore, Japan, and other countries. The product has entered Allegheny Health Network, or AHN, in the United States, a highly influential healthcare system in the eastern U.S. with 14 leading hospitals and more than 300 clinical sites. It is also undergoing joint application and clinical promotion with several top global medical institutions.

This progress demonstrates Lujian Technology’s comprehensive strength in R&D transformation and industrialization of high-end medical devices. It also marks a key step in the commercialization of the company’s innovative technologies as they gradually enter application scenarios in leading international medical institutions.

From international qualification recognition and FDA-compliant production to product deployment in global medical networks, Lujian Technology is steadily advancing its international strategy of “technology introduction, R&D transformation, and global market implementation” along a clear development path.